Medicortex Finland Oyj

New key persons joining Medicortex Finland

Turku, Finland. Medicortex Finland Oy, a Turku based biotechnology company developing breakthrough biomarker diagnostics for brain injury detection, announces election of Anna Tenstam as a new member of company’s board of directors, as well as appointment of Mikko Laurila as Chief Financial Officer (CFO) of the company.

The Extraordinary General meeting of Medicortex held on 14th January 2022 elected Mrs. Anna Tenstam (MSc, MBA) as a new member in the company’s board of directors. Mrs. Tenstam is based in Stockholm, Sweden, and has over 30 years of leadership experience in pharmaceutical, medical devices and medical aesthetics companies worldwide. She has been involved in several successful exits and currently she is acting as a board member and advisor is several medical companies. Mrs. Tenstam has M.Sc. from the University of Uppsala and MBA from the IMD Business School in Lausanne. The other Board members of Medicortex continuing on their duties are Adrian Harel, Mårten Kvist and Tom Palenius.

In addition, Medicortex has appointed Mr. Mikko Laurila (M.Sc.Econ) as the Chief Financial Officer (CFO) of the company beginning on 1 February 2022. Mr. Laurila has served in several financial management positions, including Finance Director and Head of Treasury, at a public company Raisio Plc. Mr. Laurila is joining Medicortex from Railo Partners Oy, a private investment and advisory company. At Medicortex, Mikko Laurila will be responsible for financial management, controlling, as well as for potential mergers & acquisitions in the future. Mikko Laurila has M.Sc. in Accounting and Finance from Turku School of Economics and University of Turku, Finland.

“We are going through an exciting phase at Medicortex - I’m happy to have Mrs. Tenstam on the board of directors and Mr. Laurila in the team.” says Dr. Adrian Harel, CEO of Medicortex. “These resources strengthen our corporate governance and financial management competencies which are the expertise we will need for the planned initial public offering (IPO) and listing later this year as well as for guiding the international growth of the company.” Dr. Harel adds.



Dr. Adrian Harel - CEO
Medicortex Finland Oy
Itäinen Pitkäkatu 4 B
FI-20520 Turku
Tel. +358 (0) 400 488 817


About Medicortex Finland Oyj

Medicortex Finland Oyj
Medicortex Finland Oyj
Itäinen Pitkäkatu 4 B
20520 TURKU

About Medicortex

Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect head injuries in an easy way. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Once the company completes the biomarker development its next goal will be to develop an innovative drug to halt the progression of brain injury and reduce secondary degeneration. Medicortex was founded by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) and the company is based in Turku, Finland.

Subscribe to releases from Medicortex Finland Oyj

Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oyj

Medicortex Finland Plc appointing new members for the Board of Directors3.5.2024 09:51:16 EEST | Press release

Medicortex Finland Plc, a biotechnology company located in Turku, Finland, with a proprietary biomarker technology for detection of traumatic brain injury (TBI), announces appointment of Nils Grönberg and Ville Ranta-Panula (MSc, MBA) as new members in company’s Board of Directors. Grönberg and Ranta-Panula supplement the team of scientists and clinicians with their diverse expertise in business development and management, among other skills.

Turun kaupunki myönsi Medicortexille TKI-setelin15.6.2023 13:21:40 EEST | Tiedote

Medicortex Finland Oyj, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut 5000 euron arvoisen TKI (tutkimus, kehitys- ja innovaatio-osaaminen) -setelin Turun kaupungilta. Seteli käytetään Turun yliopiston kanssa yhteistyössä tehtävän tutkimushankkeen edistämiseen. Hankkeen tarkoituksena on tutkia sähkömagneettisen säteilyn vaikutusta keskushermostoon koe-eläinmallissa.

Medicortexin kevään 2023 osakeanti päättynyt – yhtiö kiitollinen yleisön mielenkiinnosta30.5.2023 10:45:00 EEST | Tiedote

Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen osakeantikampanjan toisen kierroksen. Kampanjan aikana, joka sijoittui 2023 vuoden ensimmäiselle puolikkaalle, yritys keräsi yli 110 000 euroa. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.

Medicortex concluding the fundraising round of spring 2023 – company grateful for the public interest30.5.2023 10:45:00 EEST | Press release

Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics for mild traumatic brain injury (TBI), and drug development for the same indication, announces completion of a second round of the fundraising campaign. In the two funding rounds that took place in the first half of 2023, the company has raised more than 110,000 euros. The funds raised will be used to activate research projects in parallel to company’s main product development program.

HiddenA line styled icon from Orion Icon Library.Eye